导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.78% | 4152/4773 |
| 近一周 | -2.86% | 4332/5465 |
| 近一月 | -3.01% | 2095/5421 |
| 近一季 | -5.25% | 2014/5231 |
| 近半年 | -12.77% | 3824/4920 |
| 近一年 | -16.90% | 3849/4394 |
| 近两年 | 17.29% | 2696/2954 |
| 近三年 | 9.46% | 1774/2253 |
| 成立以来 | 33.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.21% 4265/4961 |
-7.22% 3774/5312 |
- - |
- - |
| 2025 | 10.29% 2823/4813 |
4.82% 877/3635 |
-4.30% 3468/4076 |
12.93% 3029/4524 |
-2.64% 3182/4813 |
| 2024 | 24.83% 276/3463 |
5.21% 390/2808 |
-1.36% 1045/3014 |
17.20% 1244/3129 |
2.63% 917/3463 |
| 2023 | -5.75% 773/2656 |
3.25% 1230/2280 |
-1.26% 463/2385 |
-1.90% 597/2515 |
-5.76% 1495/2655 |
| 2022 | -17.04% 546/2207 |
-18.42% 1335/1919 |
16.07% 157/2016 |
-14.18% 1043/2113 |
2.08% 1046/2208 |
| 2021 | 0.20% 723/1822 |
-2.19% 594/1255 |
3.81% 954/1330 |
-7.12% 1024/1466 |
6.25% 222/1822 |
| 2020 | 36.33% 397/1250 |
-9.78% 719/1028 |
16.90% 403/1067 |
14.95% 248/1164 |
12.46% 464/1184 |
| 2019 | 29.32% 507/1092 |
24.61% 500/754 |
-6.44% 508/804 |
1.84% 351/850 |
8.92% 272/918 |
| 2018 | -31.75% 505/834 |
- - |
- - |
- - |
-11.86% 369/691 |
| 2017 | 4.31% 419/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证全指可选消费联接C VS. 长安沪深300非周期A(740101) |